NĒRx-329

NĒRx-329 (RPA inhibitor): This lead candidate demonstrates a strong mechanism of action as a competitive inhibitor of DNA binding, exhibiting excellent solubility and stability. In vivo efficacy across multiple cancer models shows significant anti-cancer activity as a standalone treatment, and it is also effective when used in combination with DNA damage response (DDR) targeted therapies. NĒRx-329 is now ready for pre-IND enabling studies, with Phase 1/2 initiation expected in 2025.